A patient receiving cytotoxic chemotherapy for acute myeloid leukemia arrives at the oncology triage unit reporting severe chills and a recorded temperature of (). Her blood pressure is , and her heart rate is . She has an indwelling totally implantable venous access device. Laboratory analysis reveals an absolute neutrophil count of .
Arrange the following interventions in the most appropriate sequential order for managing this patient's condition according to standard clinical guidelines for high-risk febrile neutropenia.
- 1Obtain paired blood cultures from the indwelling central venous port and a peripheral site.
- 2Administer immediate empiric intravenous antipseudomonal therapy with a beta-lactam agent.
- 3Reassess the clinical response and preliminary microbiological data at 48 to 72 hours.
- 4Add empiric antifungal coverage (e.g., an echinocandin) if the patient remains febrile and neutropenic after 4 to 7 days.
Answer
The correct sequence is: Obtain blood cultures, administer empiric antipseudomonal beta-lactam therapy, reassess clinical response at 48-72 hours, and finally add empiric antifungal therapy if fever persists after 4-7 days.
High-risk febrile neutropenia is an infectious disease emergency. The standard sequence of care dictates immediately drawing blood cultures to identify the pathogen, followed promptly (within 60 minutes) by empiric broad-spectrum antibiotics with antipseudomonal activity. Once stabilized, the patient is reassessed at 48 to 72 hours when preliminary microbiological data is available. If the patient remains persistently febrile and profoundly neutropenic for 4 to 7 days despite appropriate antibacterial therapy, an occult invasive fungal infection is highly suspected, warranting the sequential addition of empiric antifungal coverage.
Step-by-Step Solution
Key Concept
Chronological management of high-risk febrile neutropenia